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Summary Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFNa-2a) and
interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal
cancer. This phase II study was designed to evaluate the anti-tumour activity and toxicity of the combination
of IL-2, IFNot-2a and 5-FU in patients with advanced colorectal cancer. Forty-four patients with metastatic
colorectal cancer were treated, predominantly on an outpatient basis, with subcutaneous IFNa-2a and IL-2
three times per week followed by once a week bolus intravenous 5-FU injections. There were six (14%) partial
responses among the 43 evaluable patients [95% confidence interval (CI) 5-28%]. Twenty-four patients had
stable disease (56%) and 13 patients (30%) showed progressive disease. The median time to progressive disease
in 43 patients was 19 weeks (range 2-72 weeks) and in responders 34 weeks (range 24-30 weeks). The median
overall survival was 47 weeks (range 2-85 weeks) and in responders 60 weeks (range 35-71 weeks).
Treatment-related toxic effects included fatigue, nausea and vomiting. Granulocytopenia was the main reason
for the dose reductions or treatment interruptions in 32 out of 44 patients. One patient died of toxicity due to
renal failure. Serial assessments of immunophenotyping and cytolytic activities ofperipheral blood lymphocytes
did not show changes in the numbers of circulating natural killer (NK) cells or in the levels of NK and
lymphokine-activated killer (LAK) cytolytic activities. This regimen of IL-2 and IFNa-2a with 5-FU has only
modest anti-tumour activity in advanced colorectal cancer.
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The treatment of advanced and metastatic colorectal cancer
remains unsatisfactory despite the availability of many
cytotoxic agents. Since 1957, 5-fluorouracil (5-FU) has been
the mainstay of therapy for disseminated colorectal cancer
(Heidelberg, 1957). Biochemical modulation of the effect of 5-
FU with methotrexate or with leucovorin has marginally
improved survival (Moertel, 1994). Another approach
appears to be the combination of 5-FU with interferon-
alpha (IFNcx-2a) (Wadler et al., 1989; Pazdur et al., 1990;
Kemeny et al., 1990). A potential way to improve the
reported results further was suggested by Onodera et al.
(1990). They studied the effects of 5-FU + leucovorin on the
interleukin 2 (IL-2)-related lymphocyte immune response.
Rather than being immunosuppressive, the use of 5-FU +
leucovorin appeared to augment natural killer (NK) and
lymphokine-activated killer (LAK) activity. Promising clinical
results were recently reported by Yang et al. (1993) applying
a combination of 5-FU, leucovorin and IL-2, and by
Atzpodien et al. (1994) using a combination of 5-FU, IL-2
and IFNa-2a in metastatic colorectal cancer. These studies
provided the basis for the design of the study reported here
with a schedule of IL-2, IFNa-2a and 5-FU in patients with
advanced colorectal cancer. We used the combination of
IFNa-2a and IL-2 upfront based on preclinical and clinical
data suggesting synergistic anti-tumour activity of this
schedule (Cameron et al., 1988; Rosenberg et al., 1989).
IFNcx can up-regulate expression of major histocompatibility
class I antigens (MHC-I) on tumour cells (Weber and
Rosenberg, 1988), which are usually down-regulated when
the tumour becomes more invasive (Feldman and Eisenbach,
1991; Smith et al., 1988). IFNoc augments LAK activity
(Chikhala et al., 1990) and has direct antiproliferative and
cytotoxic properties against tumour cells (Gresser, 1989).
These properties may alter the malignant phenotype of
tumour cells so that they become more susceptible to the
cytolytic activity of immune cells.
Materials and methods
Patient eligibility
Patients were required to have histologically confirmed
metastatic or locally advanced measurable adenocarcinoma
of the colon or rectum not previously treated with systemic
therapy. Patients were required to be <75 years of age, to
have a neutrophil count of ) 1.5 x I09 1` and a platelet
count of > 100 x 109 11, serum bilirubin 1.25 x upper limit
of normal unless due to metastatic liver disease, serum
creatinine < 1.25 x upper limit of normal, life expectancy >3
months, normal cardiopulmonary function as assessed by
non-invasive clinical examination and a Karnofsky score
>70. Patients with evidence of symptomatic CNS metastases,
positive for anti-HIV antibodies or HBsAg, or requiring
glucocorticoid administration were excluded. Written in-
formed consent was obtained from all patients before entry
into this study.
Pretreatment evaluation
Prestudy screening included: clinical assessment; haematology
tests including white blood cell count and differential, platelet
count and haemoglobin; biochemistry including bilirubin,
alkaline phosphatase, ALAT, ASAT, electrolytes, creatinine;
special laboratory tests including prothrombin, partial
thromboplastin time, thyroxine, thyrotropin, thyroglobulin,
anti-thyroid microsomal antibodies, HIV-antibody and HBs-
antigens; chest radiography; ECG; and computerised tomo-
graphy (CT) of the chest and abdomen. Serum samples of
anti-IL-2 and anti-IFNoc-2a antibodies were taken before
treatment and were repeated before each cycle. Antibody
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analysis was performed by enzyme immunoassay (EIA) in
screening for binding antibodies and by a biological assay for
the detection of neutralising antibodies.
Treatment
The treatment regimen is shown in Table I. The first 6 week
cycle consisted of IFNo-2a (Roferon-A, Hoffmann La Roche,
Basle, Switzerland) 9 MIU subcutaneously (s.c.) three times a
week (t.i.w.) for 6 weeks except for day 1 in week 2; IL-2
(Proleukin, Chiron BV, Amsterdam, The Netherlands) 9
MIU s.c. t.i.w. weeks 2 to 5, preceded by loading doses of 9
MIU s.c. three times a day on days 1 and 2 in week 2; and 5-
FU at a dose of 750 mg m-2 per day as continuous
intravenous (i.v.) infusion on days 15-20 followed by i.v.
bolus injections of 750 mg m-2 on days 29 and 36.
Thereafter, a maximum of five 4 weekly cycles were
administered, consisting of IFNa-2a 9 MIU s.c. t.i.w. for 4
weeks; IL-2 9 MIU s.c. t.i.w. for 3 weeks; and 5-FU
750 mg m-2 i.v. bolus weekly for 4 weeks.
Evaluation of toxicity, dose modifications and concomitant
medication
Toxicity was graded according to the WHO criteria (WHO,
1979) and assessed weekly.
No dose modifications were required in the case of grade I
toxicity. In the case ofgrade II toxicity, the dose of 5-FU had
to be reduced to 500 mg m-2; IFNoa-2a to 4.5 MIU and IL-2
to 4.5 MIU. If recovery occurred within 1 week, the three
drugs were given at full dose. If the toxicity recurred, the
decreased dose was reintroduced. In the case of grade III
toxicity, all three drugs were discontinued. If recovery to
grade 0 occurred within 28 days of treatment discontinuation,
5-FU was resumed at 500 mg m2, IFNa-2a at 4.5 MIU and
IL-2 at 4.5 MIU. If no full recovery occurred within 28 days
or there was occurrence of any grade IV toxicity, the patient
went off-study.
Patients could be given paracetamol 500 mg six times daily
to reduce flu-like symptoms; codeine phosphate 30 -60 mg four
times daily for diarrhoea; sucralfate mouthwash for stomatitis;
and metoclopramide or a 5HT3 antagonist for nausea and/or
vomiting. Patients were substituted with laevothyroxine in case
of hypothyroidism. Other concomitant anti-tumour therapies
or systemic steroids were not allowed.
Definition of response and statistical analysis
Tumour assessment was performed according to WHO
criteria (WHO, 1979). Evaluation of response was performed
after the second, fourth and sixth cycles. Further therapy was
withheld in case of progressive disease (PD) at any time. In
case of no response in the first 10 patients treated for at least
10 weeks, the trial was to be terminated. Otherwise, the
sample size was to be large enough to confirm or exclude a
40% response rate by 95% confidence intervals using
Pearson Clopper range limits.
Overall survival and time to disease progression were
calculated from the start of treatment until the date of
death or progression. The Kaplan-Meier method was used
to calculate the probability of survival or time to
progression.
Immunological monitoring
Absolute numbers of lymphocyte subsets and cytolytic
activities of peripheral blood mononuclear cells (PBMCs)
were assessed immediately before and at the end of the first,
second and third weeks of the first cycle, immediately before
the second, third and fourth cycles (i.e. weeks 6, 10 and 14)
and at the end of the fourth cycle (i.e. week 18). The PBMCs
were isolated by Ficoll-Isopaque density centrifugation of
30 ml heparinised venous blood samples. An aliquot was
processed immediately for immunophenotyping and the
remainder was cryopreserved in liquid nitrogen to allow the
cytotoxicity assays on all samples from a single patient to be
tested on the same occasion, to exclude the effects of
interassay variability. The lymphocyte subsets defined by
CD3 and CD56, CD4 and CD8, CD16 and CD19
monoclonal antibodies were assessed by multicolour immu-
nofluorescence and flow cytometry as described elsewhere
(Gratama et al., 1996). Cytolytic activities were determined
by a standard 3 h 5'Cr-release assay as described previously
(Gratama et al., 1993). The K562 erythromyeloid leukaemia
cell line and the Daudi Burkitt's lymphoma cell line were
used as sources of target cells for the assessment of NK and
LAK activities respectively.
Results
Patients
Fifty-one patients were entered in this study between January
1991 and September 1992. Six patients were considered
ineligible because they did not fulfil the inclusion criteria. One
patient withdrew consent, and another patient was not
evaluable for response because no post-treatment tumour
assessment was available. Thus, 43 patients were evaluable
for response and 44 for toxicity.
The patient characteristics are shown in Table II.
Evaluation of toxicity
A total of 159 treatment cycles were given, with a median
of four per patient. One patient died from treatment-related
renal failure. There were no other cases of drug-related
renal toxicity or other grade IV toxicities. Table III
summarises the percentage of patients experiencing WHO
grade II-IV toxicities. The most frequently occurring grade
III adverse events were fatigue, nausea and vomiting.
Thirty-two patients required one or more temporary dose
reductions or treatment interruptions, mostly because of
granulocytopenia.
The mean total dose per cycle of the trial medication in
Table I Immunotherapy in advanced colorectal cancer: treatment scheme
Drug Dose Schdule
IFNa-2a 9 million U s.c. Cycle 1: 3 times per week, weeks 1 and 3-6
2 times per week, week 2
Cycles 2-6 3 times per week, weeks 1-4
IL-2 9 million IU s.c. Cycle 1: 3 times daily, days I and 2 and once daily, day 3 in week 2
3 times per week, weeks 3-5
Cycles 2-6: 3 times per week, weeks 1-3
5-FU 750 mgm-2 per day Cycle 1: c.i.v. day 1-5, week 3
i.v. bolus once weekly, weeks 5 and 6
Cycles 2-6: i.v. bolus once weekly, weeks 1-4
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relation to the planned dose is shown in Table IV. It appears
that the percentage dosage actually given decreases with the
number of cycles.
Immunological monitoring
Lymphocyte subset enumerations and assays of cytolytic
functions were performed in 24 of the 43 evaluable patients
(Figure 1). Before therapy, the median values of the absolute
numbers of NK lymphocytes (CD56+,3-; Figure la) and
cytotoxic/suppressor T lymphocytes (CD8+; Figure Id) were
at the upper limit of the normal range, and the absolute
number of lymphocytes (CD3+; Figure lb) was within the
normal range, while that of the helper/inducer T lymphocytes
(CD4+; Figure ic) was slightly below the normal range.
These lymphocyte subset counts remained essentially un-
changed throughout the period of treatment and shortly
thereafter. Before therapy, the median NK activity of
peripheral blood lymphocytes was increased (Figure le),
while LAK activity was absent in most donors (Figure If).
The median values of both activities increased slightly during
the first therapeutic cycle to persist at those levels thereafter,
Table II Patients' characteristics
Sex
Men
Women
Age
Median
Range
Karnofsky score
90- 100
80
70
Sites of disease
Liver
Lung and pleura
Lymph nodes
Peritonuem
Skin
Other
25
19
59
31 -71
28
12
4
35
11
6
4
4
13
Table III Side-effects observed in 44 patients (159 courses, analysed
according to the highest toxicity-grade per patient)
No. of WHO grade (%)
Adverse eventsa patients II III IV
Fever 34 63 7
Fatigue 34 56 12
Nausea -vomiting 32 49 23
Stomatitis 19 28 7 -
Diarrhoea 24 28 2
Cutaneous 14 14
Local inflammation at 10 21
injection site
Hypotension 9 9
Granulopenia 16 23 10
Renal 1 - - 2
aPercentage ofpatients with the highest degree of an adverse event.
i.e. increased relative to the normal range for NK activity
and within the normal range for LAK activity.
Antibody formation against IL-2 and IFNae-2a
Serial serum samples of 29 patients were available. Thirteen
(45%) developed antibodies against IFNax-2a and six (21%)
against IL-2. Three (10%) had antibodies against both IL-2
and IFNa. Two of these three patients achieved a partial
response (PR) despite the presence of neutralising antibodies.
Two patients (7%) had anti-IFNcx-2a antibodies at baseline;
none had anti-IL-2 antibodies at baseline. The development
of antibodies did not appear to be related to specific side-
effects or severity of side-effects.
Response to treatment
Six of the 43 patients evaluable for response achieved a
partial response. Thus, the overall response rate was 14%
(95% confidence interval 5-28%). Twenty-four patients
(56%) had stable disease and 13 (30%) showed progressive
disease. The median time to progressive disease in 43 patients
was 19 weeks (range 2-72) and in responding patients 34
weeks (range 24-36). The median overall survival was 47
weeks (range 2-85) and in responding patients 60 weeks
(range 35-71).
Discussion
Preclinical studies have previously shown a synergistic
interaction between 5-FU and IFNa (Miyoshi et al., 1983;
Elias and Crisman, 1988), which formed the basis of the
investigation of this combination in patients with advanced
cancer. Initial clinical studies (Wadler et al., 1989; Pazdur et
al., 1990; Kemeny et al., 1990) had suggested higher response
rates than usually achieved with 5-FU alone.
Other preclinical data suggested synergy between IL-2 and
IFNa (Cameron et al., 1988), which appeared to be
confirmed in clinical studies in melanoma and renal cancer
(Rosenberg et al., 1989; Marincola et al., 1995). The logical
next step was to study the combination of the three drugs.
However, we observed a meagre 14% partial response rate
with a median response duration of 34 weeks. Although 78%
of the patients completed at least two full courses, 32 of them
(63%) required treatment interruptions or dose reductions.
The most common reason for this was granulocytopenia. The
majority of these dose modifications occurred during the first
two courses. Hence, one could argue that the low response
rate might be attributable to the moderate dose intensity
achieved. Another possible reason could be the fact that 5-
FU, in this study, was administered after IL-2 and IFNoc-2a,
thereby not taking full advantage of the possible eradication
of T-suppressor cells with chemotherapy before immunother-
apy (Berendt and North, 1980). It was also found that 5-FU
cytotoxicity was enhanced by concomitant or subsequent
exposure to IFNa, whereas the reverse sequence, IFNoa
followed by 5-FU, abrogated the cytotoxic effect of 5-FU,
suggesting that pretreatment with IFNoa could protect tumour
cells (Wadler et al., 1988). Prolonged administration of IFNa
(i.e. three times a week) can induce a persistent block of
tumour cells in Go-GI, thus reducing the S-phase fraction
and thereby diminishing the anti-cancer activity of 5-FU
(Cascinu et al., 1993). To date, we have deliberately chosen a
regimen using a loading dose of IL-2 and IFNa-2a preceding
5-FU in order to enable up-regulation of MHC-I molecules
on tumour cells (Weber and Rosenberg, 1988), to augment
LAK activity (Chikhala 1990) and to exploit the antiproli-
ferative and cytotoxic properties of IFNoc (Gresser, 1989).
However, we did not observe any changes in the tested
immune parameters throughout the study. Occasionally, the
lack of anti-tumour response has been associated with the
development of neutralising antibodies to IL-2 and IFNoc.
Table IV Mean total dose per cycle
IL-2 (MIU) IFNa (MIU) S-FU (mg)
received received received
Cycle (% planned) (% planned) (% planned)
l 134 (93%) 128 (84%) 9151 (96%)
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Figure 1 Median absolute numbers and ranges of CD3-,56+ NK lymphocytes (a), CD3+ T lymphocytes (b), CD4+ helper/
inducer lymphocytes (c), CD8 + suppressor/inducer lymphocytes (d), NK (e) and LAK (f) cytolytic activities of peripheral blood
mononuclear cells in 24 patients. Logarithmic scales have been used for the vertical axes in order to compress the figure. Closed
circles and vertical bars represent median values and confidence limits as defined by the 5th and 95th percentile respectively. The
shaded areas represent the normal range as defined by the 5th and 95th percentiles of 72 (a-d) and 29 (e, f) apparently healthy
controls. Cytolytic activities were expressed as the weighted mean of specific lysis of four effector to target (E:T) ratios (i.e. ranging
between 50 and 6.3), calculated for E:T ratio = 17.7 (Gratama et al., 1993).
However, in this study two of the three patients who
developed neutralising antibodies against IL-2 and IFNax-2a
nevertheless achieved a partial response.
As previously stated, at the time this study was designed,
IFNax seemed to be an effective biomodulating agent for
increasing 5-FU activity in the treatment of advanced
colorectal cancer. However, recently published randomised
studies have been unable to confirm this.
Hill et al. (1995a) randomised 155 patients to receive either
protracted continuous intravenous infusions (c.i.v.) of 5-FU
at a dose of 300 mg m-2 per day for 10 weeks in combination
with IFNax-2b 5 MIU s.c. t.i.w. or c.i.v. 5-FU only. In the 5-
FU/IFNa2b-group, there were significantly more episodes of
mucositis (P=0.008), leucocytopenia (P=0.001), granulocy-
topenia (P=0.004) and alopecia (P=0.0002). The overall
response rate in the 5-FU/IFNa-2b group was 22%, and in
the 5-FU group it was 33% (P= 0.12). With a follow-up time
of 861 days, the median survival in the 5-FU/IFNa-2b group
was 161 days, and in the 5-FU group 193 days. The
difference did not reach statistical significance. Premature
withdrawals owing to toxicity in both groups of patients were
equal and cannot explain the lack of IFNa-2b benefit.
The same group (Hill et al., 1995b) performed another
randomised controlled phase III study in advanced colorectal
cancer patients using a different dose and scheduling of 5-FU
and IFNoa-2b. At the start of treatment, 106 patients received
a continuous infusion of 5-FU at a dose of 750 mg m-2 per
day for five consecutive days. Fifty-two patients were
randomised to receive IFNa-2b at a dose of 10 MIU s.c.
t.i.w. 2-4 h after initiating 5-FU. During the second week,
these patients continued on IFN-a-2b and had the first dose
of bolus i.v. 5-FU 750 mg m-2 per day at the beginning of
a
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week 2. Fifty-four patients were randomised to receive 5-FU
alone, and this was given at the beginning of week 2.
Treatment was continued until progression of disease or
unacceptable toxicity for up to 12 months. In the 5-FU/
IFNa-2b group there was significantly more leucopenia
(P=0.013), lymphopenia (P=0.01), depression (P=0.014)
and withdrawal owing to adverse events (P=0.003). There
were four toxic deaths, all of which occurred in patients who
received IFNoa-2b. The overall response rate was 19% (all
PRs) in the group that received 5-FU + IFNa-2b and 30%
in the 5-FU-alone group (three complete responses (CRs) and
13 PRs) (P=0.21). Neither progression-free survival nor
overall median survival showed any significant differences in
the two groups.
Likewise, in a randomised phase III study performed by
the Corfu-A Study Group (1995), the biochemical modula-
tion of 5-FU by either IFNoc-2a or leucovorin was studied. In
247 patients, 5-FU was given at a dose of 370 mg m-2 per
day i.v. bolus for 5 days in combination with leucovorin (LV)
200 mg m-2 per day i.v. for 5 days, repeated every 4 weeks.
The other group consisted of 245 patients, who received 5-
FU 750 mg m-2 per day c.i.v. for 5 days, followed after a 9-
day interval by a weekly bolus i.v. injection at the same dose
in combination with IFNa-2a 9 MIU s.c. t.i.w. throughout
the treatment period. In the 5-FU/LV-group, there were more
gastrointestinal toxicities, while in the 5-FU/IFNoa-2a-group
the regimen was more myelosuppressive (P=0.0001). The
overall response rate in the 5-FU/LV-group was 18% and in
the 5-FU/IFNa-2a-group it was 21% (P=0.57). After a
follow-up period of 20 months, the median survival time for
the 5-FU/LV-group was 11.3 months vs 11 months for the 5-
FU-IFNoc-2a-group (P=0.98). These results suggested that
biochemical modulation of 5-FU by either leucovorin or
IFNa-2a yields similar response and survival data. The
addition of IFNa-2a to high-dose 5-FU plus leucovorin was
studied by Kohne et al. (1995) in a three-arm randomised
study. Chemotherapy-naive patients were randomised to
receive 5-FU 2600 mg m-2 i.v. as a 24 h infusion, combined
with either leucovorin 500 mg m-2 as a 2 h infusion (arm A),
or IFNa-2b 3 MIU s.c. t.i.w. (arm B), or the combination of
leucovorin plus IFNa-2b as in arms A and B (arm C).
Treatment was repeated weekly for 6 weeks followed by a 2
week rest period until tumour progression.
Because of the occurrence of two toxic deaths (septicaemia
due to mucositis and diarrhoea) among the first 17 patients
treated in arm C, the 5-FU dose was reduced to
2000 mg m2 for all patients in arm C. Despite this dose
reduction, another patient died of severe diarrhoea. An
interim analysis was then performed after the first 93 of 149
randomised patients. Among patients treated in arm A and in
arm C objective tumour responses occurred in 39% (95%
confidence interval 21-56%) and in 38% (95% confidence
interval 20-56%) respectively. This interim analysis showed
that the rates of objective responses observed in treatment
arm A and C were equivalent. As a result of the increased
toxicity observed in arm C, this treatment arm was closed.
No report on the response rate in treatment arm B was given
because randomisation between arm A and arm B was
continuing. The authors concluded that the addition of
IFNa-2b to 5-FU plus leucovorin did not increase efficacy
and was associated with life-threatening toxicity.
Heys et al. (1995) performed a randomised controlled
phase III study comparing the efficacy of 5-FU plus
leucovorin (5-FU/LV) with 5-FU plus leucovorin plus IL-2
(5-FU/LV/IL2) in patients with unresectable or metastatic
colorectal cancer. In the 5-FU/LV group, 68 patients
received 5-FU 600 mg m-2 per day bolus i.v. once a week
for 6 weeks in combination with leucovorin 25 mg m-2 per
day bolus i.v. to be repeated after 2 weeks' rest. In the 5-
FU/LV/IL2 group, 65 patients received IL-2 18 MIU m-2
per day c.i.v. from day 1 to 5, followed by 5-FU
600 mg m-2 per day bolus i.v. in combination with
leucovorin 25 mg m-2 per day i.v. on days 7, 14 and 21.
This treatment regimen was repeated on day 28. The
objective response rates were not significantly different in
both arms - 16% for 5-FU/LV and 17% for 5-FU/LV/IL2.
With a follow-up duration of 30 months, there was no
difference in the median survival, being 11.7 months and
11.4 months (P=0.11) respectively. Finally, in a small phase
II study in 18 patients Ridolfi et al. (1994) only achieved a
5% response rate using 5-FU, leucovorin, IL-2 and IFNoa in
advanced, pretreated colorectal cancer.
Despite different scheduling of IFNc and IL-2 in
combination with different doses of 5-FU with or without
leucovorin, all of these studies show that the addition of
IFNa and IL-2 failed to improve clinical benefit over 5-FU
alone. Apparently, in this case, observations from laboratory
studies cannot be translated clinically.
We conclude that our schedule of IL-2 and IFNa-2a
combined with 5-FU has only modest anti-tumour activity,
which does not appear to be better than the expected effect of
5-FU alone. This is confirmed by randomised studies that
failed to confirm the ability of IFNa and/or IL-2 to augment
the efficacy of 5-FU. In our opinion, further clinical
investigation of IFNoa and IL-2 in combination with 5-FU
in advanced colorectal cancer is not justified.
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